Previsioni

Il prezzo obiettivo medio degli analisti è +88,39€ (−3,35%). La mediana è +90,10€ (−1,48%).

Acquista	18
Mantieni	8
Vendi	1

Notizie Vai al feed delle notizie

Halozyme hits record high of $109.59 after strong quarterly results

Halozyme's stock climbed to an all-time high of $109.59 and is up about 62% year-to-date. In the second quarter the company beat expectations with non-GAAP earnings of $2.28 per share (expectation $1.81) and revenue of $481 million (forecast $401.27 million). Halozyme raised its full-year guidance, attributing the revision to record licensing revenue and robust growth in partner drugs. Several analysts raised estimates or price targets, and one analysis still sees the stock trading below its fair value despite the rally. » Altro su de.investing.com
Halozyme appoints Dannielle Appelhans to the board of directors

Halozyme has appointed Dannielle Appelhans to its board of directors. Appelhans is currently president and CEO of COUR Pharmaceuticals and negotiated there a strategic collaboration with Genentech worth up to $1 billion. She was previously CEO of Rubius Therapeutics and held leadership roles at Novartis, including senior vice president and chief technical officer of Novartis Gene Therapies, as well as positions at McKinsey and Eli Lilly. The company describes Appelhans’s operational and manufacturing expertise as a fitting complement to its growth strategy. » Altro su de.investing.com
Halozyme Therapeutics reaches record high at $104.86

Halozyme Therapeutics' stock climbed to a record high of $104.86 and is currently trading at $104.93, representing a market capitalization of about $11.88 billion. Year-to-date the stock is up roughly 53%, nearly 41% over six months and 49.33% over one year. Halozyme beat expectations in Q2/2026 with a non-GAAP earnings of $2.28 per share (expectation $1.81) and revenue of $481 million (expectation $401.27 million), driven by record license revenues; the company raised its full-year guidance. Analyst reactions: Citizens raised its price target to $93, H.C. Wainwright reiterated a buy rating with a $115 target, and three analysts raised their estimates. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2022, Halozyme Therapeutics ha già distribuito 0,26€ di dividendi. L'ultimo pagamento è avvenuto a marzo 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Halozyme Therapeutics ha registrato ricavi pari a 421,46M€ e un utile netto di 201,45M€

(EUR)	giu 2026	YoY
Ricavi	+421,46M	52,51%
Utile lordo	+352,09M	58,64%
Utile netto	+201,45M	43,77%
EBITDA	+280,39M	43,82%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+10,90Mld€
Numero di azioni	118,61M
Massimo/minimo a 52 settimane	+94,09€ - +52,54€
Dividendi	No
Beta	0,85
Rapporto P/E	+30,41
Rapporto PEG	−1,42
Rapporto P/B	+87,47
Rapporto P/S	+7,63

Profilo aziendale

Halozyme Therapeutics, Inc. ist als biopharmazeutisches Technologieplattformunternehmen in den Vereinigten Staaten, der Schweiz, Irland, Belgien, Japan und international tätig. Die Produkte des Unternehmens basieren auf der ENHANZE-Arzneimittelverabreichungstechnologie, einem patentierten rekombinanten menschlichen Hyaluronidase-Enzym (rHuPH20), das die subkutane Verabreichung von injizierbaren Biologika wie monoklonalen Antikörpern und anderen therapeutischen Molekülen sowie kleinen Molekülen und Flüssigkeiten ermöglicht. Das Hauptprodukt des Unternehmens ist Hylenex rekombinant, eine Formulierung von rHuPH20 zur Erleichterung der subkutanen Flüssigkeitsverabreichung, um die Dispersion und Absorption anderer injizierter Medikamente bei der subkutanen Urographie zu verbessern und die Resorption von Röntgenkontrastmitteln zu erhöhen. Das Unternehmen entwickelt auch Perjeta, RITUXAN HYCELA und MabThera SC für die Behandlung von Non-Hodgkin-Lymphomen und chronischer lymphatischer Leukämie (CLL), RITUXAN SC für Patienten mit CLL und HYQVIA für die Behandlung von Immunschwächekrankheiten. Darüber hinaus entwickelt das Unternehmen Tecentriq zur Behandlung von nicht-kleinzelligem Lungenkrebs, OCREVUS zur Behandlung von Multipler Sklerose, DARZALEX zur Behandlung von Patienten mit Amyloidose, schwelendem Myelom und Multiplem Myelom, Nivolumab zur Behandlung von soliden Tumoren, ARGX-113, einen menschlichen neonatalen Fc-Rezeptor, ARGX-117 zur Behandlung von Autoimmunerkrankungen und BMS-986179, einen Anti-CD-73-Antikörper. Das Unternehmen kooperiert mit F. Hoffmann-La Roche, Ltd; Hoffmann-La Roche, Inc; Baxalta US Inc; Baxalta GmbH; Pfizer Inc; Janssen Biotech, Inc; AbbVie, Inc.Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; und ViiV Healthcare Limited für kleine und große Molekül-Targets zur Behandlung und Prävention von HIV. Halozyme Therapeutics, Inc. wurde 1998 gegründet und hat seinen Sitz in San Diego, Kalifornien.

Nome	Halozyme Therapeutics
CEO	Helen I. Torley
Sede centrale	San Diego, ca Stati Uniti
Sito web	halozyme.com
Settore	Sanità
Industria	Biotecnologia
Quotazione in borsa	03/10/2008
Dipendenti	423